Isomorphic Labs, the drug-discovery spin-off of Google DeepMind, has unveiled IsoDDE, an AI model that experts describe as a generational leap beyond AlphaFold 3 in predicting how proteins interact with drugs and antibodies. Critically, unlike the AlphaFold systems that were published openly and catalysed a wave of academic and commercial innovation, IsoDDE is entirely proprietary.

The company has released a technical report but withheld the methodology, training data, and architecture behind it. Scientists are impressed but frustrated: the model's ability to generalise to novel drug-protein interactions, the hardest problem in computational drug discovery, suggests genuine breakthroughs under the hood. With billion-pound deals already signed with Lilly, J&J, and Novartis, Isomorphic is betting that keeping its advantage private will define the next era of AI-driven therapeutics. Competitors, including the open-source Boltz-2 team, say they intend to match it.

Blackstone Life Sciences has closed a USD $6.3B raise for its dedicated BXLS platform, the largest private life sciences fund ever raised, signalling sustained institutional confidence in biopharma despite a turbulent funding environment. The oversubscribed round will back drug and medical technology development across the full commercialisation lifecycle.

Recent deployments illustrate BXLS's appetite for late-stage, high-conviction bets: USD $700M to Merck for its ADC sacituzumab tirumotecan, USD $400M into Teva's IBD programme duvakitug, and a co-funding arrangement with J&J for AML candidate bleximenib. The close arrives as broader sector indicators turn cautiously positive, VC investment in pharma rose 70% quarter-on-quarter in Q4 2025, per GlobalData - though geopolitical pressures and tariff uncertainty continue to shape strategy. With 34 prior approvals to its name, Blackstone remains one of the most consequential non-traditional capital allocators in global biopharma.

The FDA and EMA have launched a formal bilateral collaboration on artificial intelligence in medicines development, a long-overdue addition to a regulatory partnership dating back to 2004. The initiative aims to establish shared guardrails promoting responsible AI innovation while reducing regulatory uncertainty for industry. Two concrete deliverables are already in motion: ten jointly developed Guiding Principles for Good AI Practice in Drug Development, and a harmonised AI terminology glossary to enable cross-border regulatory alignment.

The principles signal a meaningful philosophical shift, from static product oversight to continuous lifecycle monitoring, and from technical validation alone toward ethics, human-centricity, and plain-language transparency. For drug developers running multi-regional trials, harmonised definitions could meaningfully reduce compliance friction. With AI increasingly embedded across discovery, manufacturing, and pharmacovigilance, this collaboration lays early groundwork for what may become a global regulatory standard.

Private biotech Korsana Biosciences is merging with Nasdaq-listed Cyclerion Therapeutics in an all-stock deal expected to close in Q3 2026, with the combined entity trading under the ticker KRSA. The transaction is backed by an oversubscribed USD $380M PIPE led by Fairmount and Venrock Healthcare Partners, with a broad syndicate including General Atlantic, RA Capital, Wellington Management, and Sanofi Ventures. Korsana's lead asset, KRSA-028, is a next-generation shuttled antibody targeting amyloid beta in Alzheimer's disease, positioned as a best-in-class challenger in an increasingly competitive space. Phase I healthy volunteer data is expected by mid-2027, with funding secured through 2029. Cyclerion, previously focused on treatment-resistant depression, effectively serves as the public vehicle. The deal gives Korsana, the seventh company to emerge from Paragon Therapeutics' platform, a well-capitalised path to clinical proof of concept.

Sun Pharmaceutical Industries shed as much as 6% on April 2nd as reports emerged that the Trump administration is preparing tariffs targeting drugmakers that have not committed to lower US prescription prices. The sell-off reflects Sun Pharma's considerable US exposure — the market accounted for 31% of total revenue in FY25, with sales reaching INR ₹16,200 crore, driven increasingly by a growing specialty portfolio including Illumya, Winlevi, and Cequa. The company's strategic pivot toward innovative medicines, which now represent roughly 20% of revenue, makes it more vulnerable than generic-focused peers to politically motivated pricing pressure. Major multinationals including Pfizer, AstraZeneca, J&J, and Merck have already struck tariff exemption deals with the administration. Sun Pharma has privately indicated it does not expect material operational impact, though its shares remained among the Nifty 50's worst performers on the day.